IMCR Immunocore Holdings plc
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1671927 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.1%
TTM net income YoY-9.9%
TTM EPS YoY-10.3%
Revenue 3-yr CAGR25.9%
Net income 3-yr CAGR—
Margins
Gross margin98.9%
Operating margin-6.8%
Net margin-7.5%
FCF margin-4.2%
EBITDA margin-5.9%
Returns
ROE-7.9%
ROA-2.9%
ROIC (approx.)—
Asset turnover0.38x
Leverage & solvency
Liabilities / assets62.8%
Debt / equity0.00x
Current ratio4.62x
Interest coverage-2.37x
Cash quality & payout
Operating cash flow / net income0.32x
Accruals ratio-1.9%
Payout ratio—
Capex / revenue1.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $400.02M | $310.20M |
| Cost of revenue | $5.09M | $2.73M |
| Gross profit | $394.93M | $307.47M |
| R&D expense | $274.87M | $222.15M |
| SG&A expense | $165.41M | $155.78M |
| Operating income | -$45.35M | -$70.46M |
| Interest expense | $12.17M | $18.84M |
| Pretax income | -$19.10M | -$52.94M |
| Income tax | $16.41M | -$1.85M |
| Net income | -$35.51M | -$51.09M |
| EBITDA | -$42.25M | -$66.26M |
| EPS (basic) | -0.71 | -1.02 |
| EPS (diluted) | -0.71 | -1.02 |
| Dividends declared per share | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 50.35M | 49.99M |
| Balance sheet | ||
| Cash & equivalents | $467.71M | $455.73M |
| Short-term investments | $396.44M | $364.64M |
| Receivables | — | $63.01M |
| Inventory | $6.74M | $5.45M |
| Current assets | $996.74M | $929.86M |
| PP&E, net | $11.46M | $10.09M |
| Total assets | $1.07B | $1.01B |
| Current liabilities | $246.70M | $212.18M |
| Total liabilities | $686.24M | $648.79M |
| Shareholders' equity | $381.03M | $360.72M |
| Shares outstanding | 50.69M | 50.06M |
| Cash flow statement | ||
| Operating cash flow | -$10.71M | $26.06M |
| Capital expenditure | $4.34M | $5.17M |
| Free cash flow | -$15.05M | $20.89M |
| Investing cash flow | -$16.34M | -$355.13M |
| Financing cash flow | $12.37M | $343.88M |
| Depreciation & amortization | $3.10M | $4.20M |
| Stock-based compensation | $37.70M | $34.19M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.